TY - JOUR
T1 - Adaptive trial designs in rheumatology: Report from the OMERACT special interest group
AU - Pickles, Tim
AU - Alten, Rieke
AU - Boers, Maarten
AU - Bykerk, Vivian
AU - Christensen, Jared
AU - Christensen, Robin
AU - van Hoogstraten, Hubert
AU - Simon, Lee S.
AU - Tam, Lai-Shan
AU - Choy, Ernest H.
PY - 2019/10
Y1 - 2019/10
N2 - Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase
AB - Objective. Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time. Methods. A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Results. Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint. Conclusion. The next step is to undertake a systematic review of adaptive designs used in early-phase
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072775404&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30770514
U2 - https://doi.org/10.3899/jrheum.181054
DO - https://doi.org/10.3899/jrheum.181054
M3 - Article
C2 - 30770514
SN - 0315-162X
VL - 46
SP - 1406
EP - 1408
JO - Journal of rheumatology
JF - Journal of rheumatology
IS - 10
ER -